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Abstract
Background: Low-risk pulmonary embolism (PE) patients may be candidates for outpatient treatment or
abbreviated hospital stay. There is a need for a claims-based prediction rule that payers/hospitals can use to risk
stratify PE patients. We sought to validate the In-hospital Mortality for PulmonAry embolism using Claims daTa
(IMPACT) prediction rule for in-hospital and 30-day outcomes.
Methods: We used the Optum Research Database from 1/2008-3/2015 and included adults hospitalized for PE (415.
1x in the primary position or secondary position when accompanied by a primary code for a PE complication) and
having continuous medical and prescription coverage for ≥6-months prior and 3-months post-inclusion or until
death. In-hospital and 30-day mortality and 30-day complications (recurrent venous thromboembolism,
rehospitalization or death) were assessed and prognostic accuracies of IMPACT with 95 % confidence intervals (CIs)
were calculated.
Results: In total, 47,531 PE patients were included. In-hospital and 30-day mortality occurred in 7.9 and 9.4 % of
patients and 20.8 % experienced any complication within 30-days. Of the 19.5 % of patients classified as low-risk by
IMPACT, 2.0 % died in-hospital, resulting in a sensitivity and specificity of 95.2 % (95 % CI, 94.4–95.8) and 20.7 %
(95 % CI, 20.4–21.1). Only 1 additional low-risk patient died within 30-days of admission and 12.2 % experienced
a complication, translating into a sensitivity and specificity of 95.9 % (95 % CI, 95.3–96.5) and 21.1 % (95 % CI,
20.7–21.5) for mortality and 88.5 % (95 % CI, 87.9–89.2) and 21.6 % (95 % CI, 21.2–22.0) for any complication.
Conclusion: IMPACT had acceptable sensitivity for predicting in-hospital and 30-day mortality or complications
and may be valuable for retrospective risk stratification of PE patients.
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Background
Acute pulmonary embolism (PE) is the most serious
clinical presentation of venous thromboembolic disease
and has an incidence in United States (US) of ~112
events per 100,000 individuals [1]. PE results in a sub-
stantial economic burden, with annual healthcare costs
per case ranging from $13,018 to $16,644 [2].
According to US and European PE treatment guide-
lines [3, 4], PE patients deemed at low-risk of experien-
cing early post-PE complications (including mortality)
and who have adequate home circumstances should be
considered candidates for treatment at home or follow-
ing an abbreviated hospital admission. While clinical
rules for the risk stratification of patients with PE are
available [5], their implementation requires access to
vital sign and laboratory data often incompletely re-
ported or not found in claims databases.
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Providing researchers, payers and hospital administra-
tors with a tool that allows them to retrospectively
estimate PE patients’ predicted early complication risk
may facilitate epidemiologic research and aid them in
making future resource utilization more efficient. The
In-hospital Mortality for PulmonAry embolism using
Claims daTa (IMPACT) prediction rule was derived [6]
and subsequently validated in multiple external adminis-
trative databases for this purpose [7, 8] and has shown
prognostic accuracy for predicting in-hospital mortality
similar to that of the PE severity index (PESI), simplified
PESI (sPESI) and Hestia criteria. However, sparse data
supporting IMPACT’s ability to predict 30-day post-PE
mortality and other complications are available [9]. Here,
we sought to externally validate IMPACT’s accuracy for
predicting in-hospital and 30-day outcomes using ad-
ministrative claims data contained in the Optum
Research Database.
Methods
The preparation of this research report was in accord-
ance with the Transparent Reporting of a multivariable
prediction model for Individual Prognosis Or Diagnosis
(TRIPOD) statement [10].
Our analysis used claims data from the Optum
Research Database spanning January 2008 through
March 2015. The Optum Research Database contains
de-identified claims data from commercial and Medicare
Advantage health plan patients and links administrative
enrollment data with medical (physician, facility) and
pharmacy claims [11]. Since this study utilized only de-
identified patient level data via methods consistent with
Health Insurance Portability and Accountability Act
(HIPAA) privacy and security requirements (i.e., individ-
ual medical records or identities were not disclosed),
institutional review board oversight was not required.
We included adult patients with an International
Classification of Diseases, ninth-edition, Clinical Modifi-
cation (ICD-9-CM) diagnosis code for PE (415.1x) in the
primary position or with a secondary diagnosis code for
PE along with a primary code for a PE-related complica-
tions (respiratory failure [518.81], cardiogenic shock
[785.51], cardiac arrest [427.5], secondary pulmonary
hypertension [416.8], syncope [780.2], thrombolysis
[99.10] or intubation/mechanical ventilation [96.04,
96.05, 96.70–96.72]). Additional inclusion criteria con-
sisted of continuous medical and prescription coverage
for ≥6-months prior and 3-months post-study discharge
or until death. Patients transferred from another health-
care facility were excluded as determination of low-risk
status by clinicians is typically performed at the time of
initial PE assessment. In addition, including transfer pa-
tients would have biased our estimates of hospital
length-of-stay.
We used the IMPACT prediction rule [estimated percent
absolute risk = 1/(1 + exp(−x)); where x = −5.833 + (0.026 ×
age) + (0.402 ×myocardial infarction) + (0.368 × chronic
lung disease) + (0.464 × stroke) + (0.638 × prior major bleed-
ing) + (0.298 × atrial fibrillation) + (1.061 × cognitive impair-
ment) + (0.554 × heart failure) + (0.364 × renal failure)
+ (0.484 × liver disease) + (0.523 × coagulopathy) + (1.068 ×
cancer)] to estimate PE patients’ risk for early all-cause
mortality [6]. This claims-based logistic regression predic-
tion tool was initially derived and internally validated in a
large US MarketScan commercial and Medicare claims
database by randomly assigning PE admissions between
April 2010 and September 2013 into derivation (80 %) and
validation (20 %) cohorts. In both cohorts, the model classi-
fied PE patients into low- and high-risk in-hospital all-
cause mortality categories with high sensitivity (87 %) and
moderate specificity (47 %). Consistent with prior studies,
patients with an IMPACT predicted mortality risk ≤1.5 %
were classified as low-risk for early mortality or other com-
plications in our analysis [6–9]. ICD-9-CM coding for all
IMPACT co-morbidities was performed according to the
original IMPACT derivation paper [6]. Whenever possible,
these co-morbidities were determined using Agency for
Healthcare Research and Quality (AHRQ) 29-comorbidity
schemas [12]; however, prior major bleeding, cognitive dys-
function, stroke, myocardial infarction and atrial fibrillation
are not included in the AHRQ 29- comorbidity score and
were thus identified using the procedural and diagnostic
codes as listed in Additional file 1. Age was determined at
time of presentation.
All-cause in-hospital and 30-day mortality as well as
30-day incidence of post-PE complications (recurrent
venous thromboembolism, rehospitalization or death)
served as a priori endpoints for this study. In-hospital
and 30-day mortality were determined using the dis-
charge status field within the claims records and from
using the Social Security Administration Death Master
File. Rehospitalization was said to occur if a patient had
a new all-cause inpatient claim anytime following dis-
charge for the index PE event through 30-days post-
admission for the index event. Recurrent venous
thromboembolism was defined as a diagnosis code for
PE or deep vein thrombosis (see Additional file 2) on an
emergency department or inpatient claim within 30-days
of the index event. Accordingly, patients not discharged
within 30-days of the index admission were not included
in measures of 30-day post-admission rehospitalization
and recurrent venous thromboembolism.
All baseline variables and endpoints were analyzed
descriptively. Counts and percentages were provided for
dichotomous or categorical variables. Means ± standard
deviations or medians with 25 %, 75 % ranges were pro-
vided for continuous variables (where appropriate). To
quantify the accuracy of IMPACT for predicting in-
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hospital and 30-day mortality as well as 30-day post-PE
complications, we calculated sensitivity (the percentage
of patients at high risk for a complication who are
correctly identified as being high risk as evidenced by a
complication occurring), specificity (the percentage of
patients at low-risk of a complication who are correctly
identified as being low-risk as evidenced by not experi-
encing a complication), positive predictive value (PPV;
the probability that in the case of being classified as
high-risk for a complication, the patient experiences a
complication) and negative predictive value (NPV; the
probability that in the case of being classified as low-risk
for a complication, the patient does not experience one)
along with 95 % confidence intervals (CIs). Area under-
the-curve (AUC) statistics were calculated to assess the
IMPACT rule’s discriminative power to correctly predict
complication occurrence. All data management and stat-
istical analysis was performed using SAS version 9.4
(SAS Institute Inc, Cary, North Carolina, USA).
Results
In total, 47,531 PE patients were identified (Table 1).
The mean patient age was 67.1 ± 15.0 years, with 63.2 %
of patients ≥65 years-of-age. A majority of patients
(63.3 %) were enrolled in Medicare Advantage plans ra-
ther than commercial insurance. The most common
IMPACT co-morbidities observed were chronic lung
disease (34.2 %), heart failure (23.1 %), atrial fibrillation
(16.4 %) and cancer (15.3 %). High-risk patients were
considerably older (mean age 72.1 versus 46.6 years,
p < 0.001) and had a higher prevalence of total comorbidi-
ties than the low-risk patients. The mean IMPACT score
was estimated to be 6.1 % ± 8.1 % for the total population,
and differed significantly between patients at low-risk
(1.1 % ± 0.3 %) or high-risk (7.3 % ± 8.6 %) for early
mortality or complications (p < 0.001).
In-hospital and 30-day mortality occurred in 7.9 and
9.4 % of patients. The observed mortality risk for pa-
tients increased as estimated IMPACT mortality risk in-
creased (see Additional file 3). A total of 20.8 % of
patients experienced any post-PE complication within
30-days of the index admission. Two-by-two cross-tables
of events for each endpoint are provided in Table 2. Of
the 19.5 % of patients classified as low-risk by IMPACT,
2.0 % died in-hospital (versus 9.4 % in the high risk
group, p < 0.001), resulting in a sensitivity and specificity
of 95.2 and 20.7 % and a NPV of 98.0 % (Table 3). Only
1 additional low-risk patient died within 30-days of ad-
mission and 12.2 % experienced a complication, translat-
ing into a sensitivity, specificity and NPV of 95.9, 21.1
and 98.0 % for mortality and 88.5, 21.6 and 87.8 % for
any complication. IMPACT’s AUCs for the in-hospital
mortality, 30-day mortality and 30-day complication
endpoints were 0.66, 0.68 and 0.62, respectively.
Median hospital length-of-stay was 4-days (25 %, 75 %
range: 2–6 days) in the low-risk group and 5-days (25 %,
75 % range: 3–9 days) in the high-risk group. The per-
centage of patients with inpatient stays ≤2-days was
32.1 % (2975 of 9259) in the low-risk group and 20.5 %
(7853 of 38,272) in the high-risk group (p < 0.001).
Discussion
The multivariable IMPACT prediction rule appeared
valid when applied retrospectively to the Optum Re-
search Database. In this and prior external validation
studies [6–9], IMPACT has exhibited sensitivity >90 %
and NPVs ≥98 % for all-cause in-hospital mortality, but
often with lower and variable specificity. While a prog-
nostic rule would ideally be 100 % sensitive and 100 %
specific; this is rarely seen in real-world scenarios. How-
ever because first and foremost clinicians aim to avoid
doing harm to their patients, high sensitivity is clearly
preferable (and low specificity is less important) when
assessing whether a PE patient could have (claims-based
tools) or should have (clinical tools) been considered for
management at home or following an abbreviated hos-
pital stay (e.g., observation status).
In this study, we also assessed 30-day all-cause mortal-
ity, and found IMPACT to have similar sensitivity and
NPV (95.9 and 98.0 %, respectively) to clinical tools such
as PESI, sPESI and the Hestia criteria [5]. These results
support those of a smaller (N = 807) single-site study of
computed tomography-confirmed PE patients published
by Weeda and colleagues [9] that compared IMPACT’s
predictive accuracy for 30-day all-cause mortality to that
of PESI, sPESI and Hestia. In the study by Weeda et al.
[9], IMPACT demonstrated comparable sensitivity and
Table 1 Baseline characteristics for low- and high-risk patients
Characteristic Total Cohort IMPACT Low-Risk High-Risk
N = 47,531 N = 9,259 N = 38,272
n (%) n (%) n (%)
Age, years
(mean ± SD)
67.1 ± 15.0 46.6 ± 11.1 72.1 ± 11.0
Myocardial infarction 1,647 (3.5) 14 (0.2) 1,633 (4.3)
Chronic lung disease 16,242 (34.2) 636 (6.9) 15,606 (40.8)
Stroke 2,177 (4.6) 15 (0.2) 2,162 (5.6)
Prior major bleeding 6,233 (13.1) 101 (1.1) 6,132 (16.0)
Atrial fibrillation 7,810 (16.4) 51 (0.6) 7,759 (20.3)
Cognitive dysfunction 6,489 (13.7) 3 (<0.1) 6,486 (16.9)
Heart failure 10,967 (23.1) 50 (0.5) 10,917 (28.5)
Renal failure 6,941 (14.6) 60 (0.7) 6,881 (18.0)
Liver disease 1,443 (3.0) 38 (0.4) 1,405 (3.7)
Coagulopathy 2,828 (6.0) 75 (0.8) 2,753 (7.2)
Cancer 7,287 (15.3) 4 (<0.1) 7,283 (19.0)
SD standard deviation
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NPV for all-cause 30-day mortality (sensitivity = 97.0 %;
NPV = 99.4 %) compared to PESI, sPESI and Hestia (30-
day mortality sensitivity range = 90.9–100 % and NPV
range = 98.6–100 %). This similar sensitivity is not sur-
prising as IMPACT contains variables (including age,
cancer, altered mental status, heart failure and chronic
lung disease) found in commonly cited clinical rules
(e.g., sPESI and/or PESI). Further, the magnitude/weight
assigned to these overlapping predictors is similar across
IMAPCT and clinical tools (e.g., altered mental status
and cancer are heavily weighted in IMPACT and PESI).
Unfortunately, we could not directly compare the prog-
nostic accuracy of IMPACT to that of clinical rules in
our analysis. While the Optum Research Database does
have an electronic health record component allowing
them to link vital signs and laboratory results to a pro-
portion of covered patients, initial a priori pilot analyses
performed in preparation for this study suggested too
limited data were available to support the measurement
of PESI, sPESI or the Hestia criteria. For this reason, and
because IMPACT was specifically designed to risk strat-
ify PE patients retrospectively using administrative
claims data, we strongly encourage it not be used to
make individual patient treatment decisions. Instead, we
believe the value of IMPACT lies in its ability to retro-
spectively identify low-risk PE patients, making it a ex-
cellent tool for payers and hospital administrators to
quickly and inexpensively benchmark rates of low-risk
PE patients treated at home or following an abbreviated
admission.
Of note, this study was the first to evaluate the accur-
acy of IMPACT for stratifying patient risk for developing
a complication (recurrent venous thromboembolism, re-
hospitalization or death) within 30-days. IMPACT’s
sensitivity for this endpoint was found to be 88.5 %;
somewhat lower than observed for either in-hospital or
30-day mortality, but still likely acceptable for many
decision-makers. This unique data demonstrating IM-
PACT’s prognostic accuracy for 30-day post-PE compli-
cations is important as various payors such as the
Centers for Medicare and Medicaid Services (CMS) con-
tinue to put pressure on providers to reduced the rate of
hospital readmissions [13].
Our study has other limitations worth discussing. First,
while claims data are extremely valuable for the efficient
and effective examination of real-world healthcare out-
comes, treatment patterns, healthcare resource
utilization and costs, all claims databases have inherent
limitations affecting their internal and external validity.
Results are dependent on the accuracy and completeness
of administrative claims data, which by nature, may be
prone to coding errors or omissions (for example, out of
hospital mortality may have been missed due to poor
reporting to the Social Security Administration and the
need to link this data to Optum claims). Moreover, some
limitation in the generalizability of results should always
be considered because claims data are collected for the
purpose of payment and not research. Second, we could
not determine if the observed mortality or complications
were attributable to the index PE, as this requires a pro-
spective design and access to detailed chart data. It is
likely some deaths or rehospitalizations were associated
with co-morbidities (i.e., cancer and heart failure) and
not directly related to the index PE. While it is unclear
what influence this had on the sensitivity and specificity
of IMPACT on our mortality and any complication end-
points, it may at least partially explain IMPACT’s re-
duced sensitivity and NPV for the any complication (30-
day recurrent VTE, rehospitalization or death from any
cause) endpoint. A final limitation includes the fact that
claims data cannot provide information on severity of
comorbidities (only their presence) and cannot fully ad-
dress other factors that may be associated with the de-
velopment of early complications (or the decision to
keep patients in the hospital longer), including socioeco-
nomic status, likely patient compliance to medical in-
structions and the presence of family support.
Conclusion
The multivariable IMPACT rule appeared valid for pre-
dicting early (up to 30-day) post-PE outcomes when im-
plemented in the Optum Research Database. IMPACT
has previously been shown to exhibit sensitivity of
~90 % and NPV ~99 % for predicting in-hospital and
30-day mortality; and in addition to confirming these
findings, this study also provides data on IMPACT’s abil-
ity to risk stratify patients for the development of recur-
rent venous thromboembolism, rehospitalization or
Table 2 2 × 2 Tables for All-Cause In-Hospital and 30-Day





IMPACT High-Risk 34,687 3,585





IMPACT High-Risk 34,013 4,259
IMPACT Low-Riska 9,076 183








IMPACT High-Risk 29,531 8,741
IMPACT Low-Riska 8,130 1,129
IMPACT In-hospital Mortality for PulmonAry embolism using Claims daTa, VTE
venous thromboembolism
aLow-risk defined as an “In-hospital Mortality for PulmonAry embolism using
Claims daTa” rule estimated risk of early complications of ≤1.5 %
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Sensitivity Specificity NPV PPV AUC
Low-risk High-risk No Yes (TP/TP + FN) (TN/TN + FP) (TN/TN + FN) (TP/TP + FP) (95 % CI)
N N N N (%, 95 % CI) (%, 95 % CI) (%, 95 % CI) (%, 95 % CI)
All-Cause In-Hospital Mortality 9,259 38,272 43,764 3,762 9.4 98.0 90.6 2.0 95.2 (94.4–95.8) 20.7 (20.4–21.1) 98.0 (97.7–98.3) 9.4 (9.1–9.7) 0.66 (0.65–0.67)
All-Cause 30-Day Mortality 9,259 38,272 43,089 4,442 11.1 98.0 88.9 2.0 95.9 (95.3–96.5) 21.1 (20.7–21.5) 98.0 (97.7–98.3) 11.1 (10.8–11.5) 0.68 (0.67–0.69)
30-Day Recurrent VTE, Rehospitalization or
Death From Any Cause
9,259 38,272 37,661 9,870 22.8 87.8 77.1 12.2 88.5 (87.9–89.2) 21.6 (21.2–22.0) 87.8 (87.1–88.5) 22.8 (22.4–23.3) 0.62 (0.62–0.63)
AUC area under the curve statistic, CI confidence interval, FN false negative, FP false positive, IMPACT In-hospital Mortality for PulmonAry embolism using Claims daTa, N number, NPV negative predictive value, PPV
















death at 30-days. While not intended for clinical
decision-making, IMPACT may be a valuable tool for
retrospective analysis or benchmarking of PE patients.
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